Humana AB (publ)

LSE:0RF7 Stock Report

Market Cap: SEK 1.9b

Humana Valuation

Is 0RF7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RF7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RF7 (SEK36.35) is trading below our estimate of fair value (SEK87.81)

Significantly Below Fair Value: 0RF7 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RF7?

Key metric: As 0RF7 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RF7. This is calculated by dividing 0RF7's market cap by their current earnings.
What is 0RF7's PE Ratio?
PE Ratio15.3x
EarningsSEK 124.00m
Market CapSEK 1.90b

Price to Earnings Ratio vs Peers

How does 0RF7's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RF7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.4x
CVSG CVS Group
22.5x15.5%UK£589.0m
SPI Spire Healthcare Group
31.4x26.9%UK£887.2m
MDC Mediclinic International
21.9x10.7%UK£3.7b
IDHC Integrated Diagnostics Holdings
13.9x23.7%US$228.5m
0RF7 Humana
15.3x44.7%SEK 1.9b

Price-To-Earnings vs Peers: 0RF7 is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does 0RF7's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0RF7 15.3xIndustry Avg. 18.6xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RF7 is good value based on its Price-To-Earnings Ratio (15.3x) compared to the European Healthcare industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is 0RF7's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RF7 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.3x
Fair PE Ratio41.3x

Price-To-Earnings vs Fair Ratio: 0RF7 is good value based on its Price-To-Earnings Ratio (15.3x) compared to the estimated Fair Price-To-Earnings Ratio (41.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RF7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 36.35
SEK 50.50
+38.9%
5.0%SEK 53.00SEK 48.00n/a2
Nov ’25SEK 38.10
SEK 49.00
+28.6%
8.2%SEK 53.00SEK 45.00n/a2
Oct ’25SEK 35.55
SEK 39.50
+11.1%
13.9%SEK 45.00SEK 34.00n/a2
Sep ’25SEK 32.60
SEK 39.50
+21.2%
13.9%SEK 45.00SEK 34.00n/a2
Aug ’25SEK 31.10
SEK 39.50
+27.0%
13.9%SEK 45.00SEK 34.00n/a2
Jul ’25SEK 33.90
SEK 37.50
+10.6%
20.0%SEK 45.00SEK 30.00n/a2
Jun ’25SEK 32.20
SEK 35.00
+8.7%
14.3%SEK 40.00SEK 30.00n/a2
May ’25SEK 29.30
SEK 35.00
+19.5%
14.3%SEK 40.00SEK 30.00n/a2
Apr ’25SEK 24.20
SEK 33.50
+38.4%
19.4%SEK 40.00SEK 27.00n/a2
Mar ’25SEK 25.30
SEK 33.50
+32.4%
19.4%SEK 40.00SEK 27.00n/a2
Feb ’25SEK 25.85
SEK 34.50
+33.5%
15.9%SEK 40.00SEK 29.00n/a2
Jan ’25SEK 28.50
SEK 37.00
+29.8%
21.6%SEK 45.00SEK 29.00n/a2
Dec ’24SEK 27.65
SEK 37.00
+33.8%
21.6%SEK 45.00SEK 29.00n/a2
Nov ’24SEK 26.70
SEK 34.50
+29.2%
15.9%SEK 40.00SEK 29.00SEK 38.102
Oct ’24SEK 26.43
SEK 34.50
+30.6%
15.9%SEK 40.00SEK 29.00SEK 35.552
Sep ’24SEK 29.65
SEK 34.50
+16.4%
15.9%SEK 40.00SEK 29.00SEK 32.602
Aug ’24SEK 28.25
SEK 34.50
+22.1%
15.9%SEK 40.00SEK 29.00SEK 31.102
Jul ’24SEK 22.45
SEK 17.00
-24.3%
14.4%SEK 20.00SEK 14.00SEK 33.903
Jun ’24SEK 15.04
SEK 17.00
+13.0%
14.4%SEK 20.00SEK 14.00SEK 32.203
May ’24SEK 14.48
SEK 16.67
+15.1%
17.2%SEK 20.00SEK 13.00SEK 29.303
Apr ’24SEK 14.70
SEK 17.33
+17.9%
11.9%SEK 20.00SEK 15.00SEK 24.203
Mar ’24SEK 14.96
SEK 17.33
+15.9%
11.9%SEK 20.00SEK 15.00SEK 25.303
Feb ’24SEK 21.53
SEK 45.67
+112.2%
47.9%SEK 70.00SEK 17.00SEK 25.853
Jan ’24SEK 39.20
SEK 64.33
+64.1%
6.3%SEK 70.00SEK 61.00SEK 28.503
Dec ’23SEK 42.95
SEK 64.33
+49.8%
6.3%SEK 70.00SEK 61.00SEK 27.653
Nov ’23SEK 41.73
SEK 71.67
+71.8%
8.7%SEK 80.00SEK 65.00SEK 26.703

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.05

7D

-4.2%

1Y

4.8%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.52

7D

-5.4%

1Y

-8.8%

Guerbet

€335.4m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.70

7D

-9.6%

1Y

50.0%